Management of Hepatic Encephalopathy with Rifaximin and Lactulose

Mechanism of Action and Therapeutic Benefits

Rifaximin is a non-absorbable antibiotic that maintains high concentration in the intestine, inhibits bacterial RNA synthesis, and has broad antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative bacteria 1
Lactulose is a non-absorbable disaccharide that reduces intestinal pH through bacterial degradation, increases lactobacillus counts, converts ammonia to less absorbable ammonium, and produces an osmotic laxative effect 2
The combination of these two mechanisms provides complementary effects in reducing ammonia levels and improving hepatic encephalopathy symptoms 1, 2

Recent clinical trials demonstrate that patients treated with rifaximin and lactulose combination show better recovery from hepatic encephalopathy within 10 days (76% vs. 44%, P=0.004) and shorter hospital stays (5.8 vs. 8.2 days, P=0.001) compared to lactulose alone 1
Patients receiving combination therapy have fewer readmissions for hepatic encephalopathy at 180 days compared to those receiving lactulose monotherapy 1, 2

Rifaximin: 400 mg three times daily or 550 mg twice daily (maximum dose 1,200 mg/day) 1, 3
Lactulose: 30-45 mL (20-30 g) every 1-2 hours initially until achieving at least 2 bowel movements per day, then titrate to maintain 2-3 soft stools daily 1, 4

The EASL Clinical Practice Guidelines strongly recommend lactulose as secondary prophylaxis following a first episode of overt hepatic encephalopathy (LoE 1, 96% consensus) 4
Rifaximin as an adjunct to lactulose is recommended as secondary prophylaxis following more than one additional episode of overt hepatic encephalopathy within 6 months of the first one (LoE 2, 92% consensus) 4
The European Association for the Study of the Liver (EASL) recommends prioritizing treatment with non-absorbable disaccharides (lactulose or lactitol) in cirrhotic patients with overt hepatic encephalopathy 4

Rifaximin might have limited use in severe hepatic encephalopathy (West-Haven criteria grade 3 or higher) due to the need for oral administration 1
For patients unable to take medications orally, lactulose can be administered via nasogastric tube or as an enema (300 mL lactulose and 700 mL water 3-4 times daily) 1

Relying solely on rifaximin without lactulose may result in suboptimal management of hepatic encephalopathy and increased risk of recurrence 1, 4
Lactulose dosing should be carefully titrated to avoid excessive diarrhea, which can lead to dehydration and electrolyte imbalances 2
The high cost of rifaximin may be a significant barrier to its routine use, but its benefits in reducing hospitalizations may offset this cost 6